Our Approach

We are advancing cancer care by developing next-generation therapies to address treatment resistance.

Leveraging our team’s deep expertise in developing targeted cancer therapies, Theseus is addressing the challenge of drug resistance by developing the next generation of tyrosine kinase inhibitors (TKIs).

Our approach has three pillars:

  1. Identifying clinically validated targets where there is a clear unmet medical need. This allows us to minimize the biological and clinical risk associated with the development of our product candidates.
  2. Structure-guided drug design with predictive screening methodologies. Our discovery engine combines a unique chemistry approach to optimize “pan-ness” combined with a novel preclinical assay that we believe can accurately predict clinical outcomes for TKIs.
  3. Translationally-driven, biomarker-guided clinical development. We employ biomarkers early on in clinical development, which allows us to assess activity against individual mutant variants.

Resistance mutations limit the efficacy of existing targeted therapies by rendering tumor cells unresponsive to drugs. Our next-generation TKIs may successfully address the challenge of resistance.

At Theseus, we are passionate about transforming the way cancer is treated. Our goal is to develop a new generation of pan-variant inhibitors to outsmart drug resistance.